IC50 for treatment with erlotinib, gefitinib or vandetanib in parental CALU-3 and HCT116 cell lines (WT) and their TKI-resistant derivatives (ERL-R, GEF-R, VAN-R).
2013
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI